Pfizer: Neoplasms, Plasma Cell trials
The registry lists 12 Neoplasms, Plasma Cell studies with Pfizer as lead sponsor. 3 are open to participants now and 6 have results posted.
Phase 1 2Phase 2 2Phase 3 1Phase 4 1No phase 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple MyelomaNot yet recruitingNCT07927023
- A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard TreatmentsNot yet recruitingNCT07881835Phase 4
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)RecruitingNCT06152575Phase 3
- A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and USCompletedNCT06504524Results posted
- A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple MyelomaCompletedNCT05932290Results posted
- A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple MyelomaCompletedNCT05565391Results posted
- A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.CompletedNCT05228470Phase 2Results posted
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAbCompletedNCT04649359Phase 2Results posted
- A Safety Study of SEA-BCMA in Patients With Multiple MyelomaTerminatedNCT03582033Phase 1Results posted
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple MyelomaTerminatedNCT03530683Phase 1
- Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and OncologyCompletedNCT02140736
- Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic PatientsCompletedNCT00195533